Literature DB >> 24589261

Ischemia-reperfusion injury in sickle cell anemia: relationship to acute chest syndrome, endothelial dysfunction, arterial vasculopathy, and inflammatory pain.

Robert P Hebbel1.   

Abstract

Ischemia-reperfusion (I/R) physiology, also called reperfusion injury, instigates vascular and tissue injury in human disease states. This review describes why sickle cell anemia should be conceptualized in this fashion and how I/R physiology explains the genesis of characteristic aspects of vascular pathobiology and clinical disease in sickle cell anemia. The nature of I/R and its relevance to sickle cell anemia are discussed, with an emphasis on the acute chest syndrome, endothelial dysfunction with aberrant vasoregulation, circle of Willis vasculopathy, and inflammatory pain. Viewing sickle disease from this perspective elucidates defining pathophysiology and identifies a host of novel potential therapeutic targets.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endothelial dysfunction; Inflammation; Ischemia-reperfusion; Sickle

Mesh:

Year:  2014        PMID: 24589261     DOI: 10.1016/j.hoc.2013.11.005

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  55 in total

1.  Targeting βCys93 in hemoglobin S with an antisickling agent possessing dual allosteric and antioxidant effects.

Authors:  Tigist Kassa; M B Strader; Akito Nakagawa; Warren M Zapol; Abdu I Alayash
Journal:  Metallomics       Date:  2017-09-20       Impact factor: 4.526

Review 2.  Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease.

Authors:  Marilyn J Telen
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

3.  Dexmedetomidine ameliorates nocifensive behavior in humanized sickle cell mice.

Authors:  Gabriela Calhoun; Li Wang; Luis E F Almeida; Nicholas Kenyon; Nina Afsar; Mehdi Nouraie; Julia C Finkel; Zenaide M N Quezado
Journal:  Eur J Pharmacol       Date:  2015-02-25       Impact factor: 4.432

Review 4.  Sickle cell disease: renal manifestations and mechanisms.

Authors:  Karl A Nath; Robert P Hebbel
Journal:  Nat Rev Nephrol       Date:  2015-02-10       Impact factor: 28.314

Review 5.  Selectins: initiators of leucocyte adhesion and signalling at the vascular wall.

Authors:  Rodger P McEver
Journal:  Cardiovasc Res       Date:  2015-05-20       Impact factor: 10.787

6.  Interventions for chronic kidney disease in people with sickle cell disease.

Authors:  Noemi Ba Roy; Patricia M Fortin; Katherine R Bull; Carolyn Doree; Marialena Trivella; Sally Hopewell; Lise J Estcourt
Journal:  Cochrane Database Syst Rev       Date:  2016-10

Review 7.  cGMP modulation therapeutics for sickle cell disease.

Authors:  Nicola Conran; Lidiane Torres
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-28

8.  Association between diffuse myocardial fibrosis and diastolic dysfunction in sickle cell anemia.

Authors:  Omar Niss; Robert Fleck; Fowe Makue; Tarek Alsaied; Payal Desai; Jeffrey A Towbin; Punam Malik; Michael D Taylor; Charles T Quinn
Journal:  Blood       Date:  2017-05-15       Impact factor: 22.113

9.  Morphine promotes neovascularizing retinopathy in sickle transgeneic mice.

Authors:  Kalpna Gupta; Chunsheng Chen; Gerard A Lutty; Robert P Hebbel
Journal:  Blood Adv       Date:  2019-04-09

10.  The heart in sickle cell disease, a model for heart failure with preserved ejection fraction.

Authors:  John C Wood
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.